IRulya Therapeutics, Inc. (IRLA)
31.00
+1.69
(+5.77%)
USD |
NASDAQ |
Nov 06, 16:00
30.85
-0.15
(-0.48%)
After-Hours: 20:00
IRulya Therapeutics Research and Development Expense (Quarterly) : 5.461M for June 30, 2026
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 5.461M |
| March 31, 2026 | 6.845M |
| December 31, 2025 | 12.60M |
| September 30, 2025 | 8.083M |
| June 30, 2025 | 6.553M |
| March 31, 2025 | 8.145M |
| December 31, 2024 | 5.825M |
| September 30, 2024 | 4.916M |
| June 30, 2024 | 4.147M |
| March 31, 2024 | 3.502M |
| December 31, 2023 | 3.434M |
| September 30, 2023 | 1.431M |
| June 30, 2023 | 1.353M |
| March 31, 2023 | 3.23M |
| December 31, 2022 | 2.768M |
| September 30, 2022 | 2.451M |
| Date | Value |
|---|---|
| June 30, 2022 | 7.199M |
| March 31, 2022 | 11.87M |
| December 31, 2021 | 15.21M |
| September 30, 2021 | 14.04M |
| June 30, 2021 | 14.72M |
| March 31, 2021 | 16.82M |
| December 31, 2020 | 15.86M |
| September 30, 2020 | 16.98M |
| June 30, 2020 | 14.09M |
| March 31, 2020 | 14.38M |
| December 31, 2019 | 10.03M |
| September 30, 2019 | 8.253M |
| June 30, 2019 | 7.109M |
| March 31, 2019 | 4.825M |
| June 30, 2018 | 2.286M |
| March 31, 2018 | 2.413M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| Korsana Biosciences, Inc. | 42.14M |
| PepGen Inc. | 12.22M |
| Q32 Bio, Inc. | 5.149M |
| Bridgebio Oncology Therapeutics, Inc. | 49.22M |
| Arrowhead Pharmaceuticals, Inc. | 192.06M |